Spanish company Cobiomic boosts precision medicine with artificial intelligence
The Spanish biotechnology company Cobiomic has announced a significant breakthrough in its ability to identify biomarkers. By combining advanced technologies, the company seeks to improve the accuracy of medical diagnoses and the development of new personalized treatments for patients.
The core of this innovation lies in the use of high-throughput proteomics. This technique allows for the analysis of thousands of proteins in a single biological sample, providing a detailed view of a person's health status. To process this vast amount of information, Cobiomic uses Olink technology, which is globally recognized for its high sensitivity in protein analysis.
In addition to laboratory technology, the company integrates artificial intelligence (AI) into its processes. The use of advanced algorithms allows for the analysis of clinical data alongside proteomic information, drastically accelerating the time required to discover new biomarkers. This approach makes it possible to identify complex patterns that would be invisible to traditional analysis methods.
This development represents an important step for the biotechnology sector in Spain. By optimizing medical research, Cobiomic not only improves the efficiency of clinical trials but also opens the door to more effective therapies tailored to the specific needs of each patient in the near future.